Therapeutic options of endometrial hyperplasia management. Current recommendations and prospective directions of treatment

Endometrial hyperplasia (EH) is a pathological condition characterized by proliferation of the endometrial glands with an increase in glands/stroma ratio compared to normal proliferative endometrium. EH precursor development one most common gynecological malignancies – cancer. There are without atypia and atypia.Total hysterectomy bilateral salpingo-oophorectomy method choice treatment atypical EH. It important eliminate risk factors overweight patients should lose weight adjusting diet, physical activity. Recently, aromatase inhibitors have also proven be effective option for atypia. Oral progestogens levonorgestrel-releasing intrauterine device methods conservative premenopausal postmenopausal women EH.However, not all can use progestins long time due possible side effects. Failure progestin may depend on various factors, such as patient’s age, health status, other conditions, degree or type hyperplasia. So it look new management adjuvant drugs that will potentiate effectiveness basic treatment, well opportunities reduce risks progesterone receptor resistance potentiation progestins. Cridanimod small molecule has been shown studies receptors expression suggested combination therapy increases thus improves treatment. Research results allows consider possibility using cridanimod complex therapy, especially against background viral infection. reduces progestogen EH, provides best result after number relapses.